Dr Udo Greiser B.Sc., PhD
Contact Details
|
 |
Biography:
| 2006-To date Principal Investigator, Enterprise Ireland Technology Development Grant 2004-To date Senior Researcher, NCBES/REMEDI, National University of Ireland, Galway, Ireland ¿Non-viral genetic modifications of stem cells¿ P.I. Prof. Timothy O¿Brien, M.D., 2001-2003 Research Scientist, Hermes Biosciences Inc., South San Francisco, CA, USA 1998-2001 Postdoctoral fellow, UCSF Cancer Center, San Francisco, CA, USA ¿Targeting immunoliposomes to vascular endothelial receptors¿ P.I. John Park, MD 1997-1998 Postdoctoral fellow, California Pacific Medical Center, San Francisco, CA, USA ¿A novel non-viral delivery system for gene therapy¿ P.I. Dr. Demetrios Papahadjopoulos 1993-1997 Ph.D (Biology/Biochemistry), Max-Planck-Group ¿Molekulare Zellbiologie¿, Friedrich Schiller University Jena/Germany ¿Lipid modulation of the epidermal growth factor signaling cascades¿ P.I. Dr. habil. Frank Boehmer/Prof. Dr. Reinhard Wetzker, 1992-1993 B.Sc., Chemistry/biochemistry ¿Signaling of the nerve growth factor¿ P.I. Prof. Dr. Rolf Heumann, Ruhr-University Bochum/Germany Publications, Posters etc. 1. 1. McMahon, JM; Conroy, S; Lyons, M; Greiser, U; O¿Shea, C; Strappe, P; Howard, L; Murphy, M; Barry, F; and O¿Brien, T., (2006) Gene transfer into rat mesenchymal stem cells: a comparative study of viral and non-viral vectors, Stem Cells and Development, 15; 87-96. 2. Mamot, C., Drummond, D.C., Greiser, U., Hong, K., Kirpotin, D.B., Marks, J.D. and Park, J.W. ¿EGFR- targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII- overexpressing tumor cells. ¿ Cancer Research 63, 3154- 3161, (2003) 3. Mamot, C., Drummond, D.C., Greiser, U., Hong, K., Kirpotin, D.B., Marks, J.D., Benz, C.C. and Park, J.W., EGFR- targeted drug delivery via immunoliposomes.¿ Proc. Am. Assoc. Cancer Res. (AACR), 43:413 (2002) 4. Greiser, U., Drummond, D.C., Mamot, C., Nielsen, U.B., Zhu, Z., Kirpotin, D.B., Marks, J.D., Hong, K., Benz, C.C. and Park, J.W., ¿Targeting immunoliposomes to endothelial receptors¿, Proc. Am. Assoc. Cancer Res. (AACR) (2002) 5. Park, J.W., Kirpotin, D.B., Hong, K., Drummond, D.C., Greiser, U., Mamot, C., Marks, J.D. and Benz, C.C.¿, Development of Immunoliposome Technology As a Targeted Drug Delivery System. ¿ NCI, 9th Spore Investigator¿s Workshop, Washington, July 15- 17, 9:49 (2001) 6. Park, J.W., Kirpotin, D.B., Hong, K., Drummond, D.C., Greiser, U., Mamot, C., Marks, J.D. and Benz, C.C. ¿Applications of Immunoliposome Technology for Targeted Drug Delivery¿, Proc. of the AACR-NCI-EORTC Meeting, Clin. Cancer Res., 7(suppl): 11, (2001) 7. Suarez- Pestana, E., Greiser, U., Sanchez, B., Fernandez, L.E., Lage, A., Perez, R. and Boehmer, F.¿, Growth inhibition of human lung adenocarcinoma cells by antibodies against epidermal growth factor receptor and by ganglioside GM3¿. British Journal of Cancer 75(2), 213-220. (1996) 8. Tomic, S., Greiser, U., Lammers, R., Kharitonenkov, A., Imyanitov, E., Ullrich, A. and Boehmer, F. ¿Association of SH2 domain protein tyrosine phosphatase with the epidermal growth factor receptor in human tumor cells- Phosphatidic acid activates receptor dephosphorylation by PTP 1C¿, J. Biol. Chem. 270, 21277- 21284 (1995) |
Research Interests
| Non-viral, liposome mediated gene delivery/ therapy antibody phage display stem cell research, cancer, cardiovascular disease signal transduction of growth factors |
Peer Reviewed Journals
| Griffin, M., Greiser, U., Barry, F., O'Brien, T., & Ritter, T. (2010) 'Genetically Modified Mesenchymal Stem'. Discovery Medicine, 9 (46):219-223. [ARAN Link] [Details] |
| Bowes T, Hanley SA, Liew A, Eglon M, Mashayekhi K, O'Kennedy R, Barry F, Taylor WR, O'Brien T, Griffin MD, Finlay WJJ, Greiser U. (2011) 'Accepted: Developing cell-specific antibodies to endothelial progenitor cells using avian immune phage display technology'. Journal of Biomolecular Screening. Impact Factor 2.4, 16 :744-754. [DOI] [Details] |